University of Illinois

Oncotech, Inc.

Onotech, Inc.

Eugene Mechetner

John P Fruehauf

Igor B Roninson

The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in chemotherapeutic drug resistant and drug sensitive tumor cells.

Methods for cancer prognosis and diagnosis

This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for identifying and characterizing anticancer compounds.

Methods and reagents for preparing and using immunological agents specific for P-glycoprotein

The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in anti-angiogenic agent-sensitive and anti-angiogenic agent-resistant vascular endothelial cells as compared to baseline vascular endothelial cells.

Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells

This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for purifying hematopoietic stems cells expressing Pgp and diagnostic and therapeutic methods for cancer cells expressing Pgp.

Methods and reagents for preparing and using immunological agents

Hybridomas (termed 'UIC2 hybridoma', ATCC Accession No. HB11027 and 'UIC2/A hybridoma', ATCC Accession No. HB11287) producing a monoclonal antibody (termed 'UIC2 mAb') directed against an extracellular domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells was produced by fusing a human myeloma cell with a spleen cell derived from a Balb/c mouse immunized with syngeneic 3T3 fibroblasts previously transfected with the isolated human mdr1 cDNA. UIC2 mAb, thus produced, as well as fragments and recombinant derivatives thereof, may be used to detect and isolate multidrug resistant primate cells and human mdr1 gene products, and to reverse multidrug resistance in primate cells, including cells of multidrug resistant human tumors.

Monoclonal antibody to a human MDR1 multidrug resistance gene product,

A hybridoma (termed 'UIC2 hybridoma', ATCC Accession No. HB11207) producing monoclonal antibodies (termed 'UIC2 mAb') directed against an extracellular domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells was produced by fusing a human myeloma cell with a spleen cell derived from a BALB/c mouse immunized with syngeneic 3T3 fibroblasts previously transfected with the isolated human mdr1 cDNA. UIC2 mAb, thus produced, as well as fragments and recombinant derivatives thereof, may be used to detect and isolate multidrug resistant primate cells and human mdr1 gene products, and to reverse multidrug resistance in primate cells, including cells of multidrug resistant human tumors.

Growing community of inventors

Irvine, CA, United States of America

Eugene Mechetner